Market Research Logo

The Global Genetic Testing Market Size, Strategies and Forecasts 2016 to 2020

The Global Genetic Testing Market Size, Strategies and Forecasts 2016 to 2020

Will all newborns receive Whole Genomic Sequencing at birth?
Our facts and support = Your success.
The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2020. The report includes detailed breakouts for 14 countries and 5 regions.
Predictive Diagnostics? Pharmacogenomic Testing? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five.
Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.


1. Introduction and Market Definition
1.1 Genetic Testing Definition
1.2 The Genomics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for laboratory testing
2. Market Overview
2.1 Market Participants
2.1.1 Supplier/pharmaceutical
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 DTC Lab
2.1.9 Independent Genetic Testing Lab Audit body
2.2 Genetic Tests –Types, Examples and Discussion
2.2.1 Preimplantation Genetic Diagnosis
2.2.2 Prenatal Diagnosis
2.2.3 Newborn Screening
2.2.2 Diagnostic Testing
2.2.3 Carrier Testing
2.2.6 Predictive and Presymptomatic Testing
2.2.7 Pharmacogenomics
2.2.8 Forensic Testing
2.2.9 Parental Testing Ancestral Testing
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.2.1 Hospital vs. Central Lab
2.3.3 Physician Office Lab’s
2.3.4 Physician’s and POCT
2.4 Profiles of Key Genetic Testing Companies
2.4.1 Roche Molecular Diagnostics
2.4.2 Illumina
2.4.3 Hologic
2.4.4 Agilent/Dako
2.4.5 Qiagen
2.4.6 Myriad Genetics
2.4.7 Becton, Dickinson & Co.
2.4.8 Abbott Laboratories
2.4.9 Cepheid
Genomic Health
Grifols
bioMérieux
Foundation Medicine
Agendia
Thermo Fisher
Signal Genetics LLC
Siemens Healthcare
2.5 Market Shares of Key Genetics Players - Analysis
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Genetic Discovery Creates New Diagnostic Markets
3.1.2 Aging Population a Boon for Diagnostics.
3.1.3 Pharmacogenomics Drives Further Growth.
3.1.4 Point of Care Testing can increase demand
3.1.5 Fertility Practice
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs.
3.2.3 Testing usage analysis curtailing growth.
3.2.4 Wellness has a downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role.
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 POCT/Self Testing Disruptive Force
3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.5 CGES Testing, A Brave New World
3.4.6 Biochips/Giant magneto resistance based assay
4. Genetic Testing Recent Developments
4.1 Recent Developments – Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
4.2 Genomic Vision Forms Strategic Partnership with University-Hospital Institute Imagine
4.3 Transgenomic Completes Sale of GAP Business Unit
4.4 Cigna Issues Coverage Criteria for Whole-Exome Sequencing; WGS Still Not Covered
4.5 Exome Sequencing Links RTTN Mutation to Primary Microcephaly, Primordial Dwarfism ...
4.6 Admera Health Announces CardioGxOne Panel
4.7 Newborns to Get Whole Genome Sequencing
4.8 Eurofins Acquiring PerkinElmer’s NTD Laboratory Services Business
4.9 GeneInsight Acquisition Boosts Sunquest's Clinical Genetics IT Platform
4.10 AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep
4.11 The Cooper Companies’ Women’s Health Care Unit Acquires Genesis Genetics
4.12 Research Validates Preimplantation Genetic Diagnosis for Aneuploidy (PGD-A)
4.13 New Investments in Ancestry.com to Boost DNA Business
4.14 GHO Capital Announces Acquisition of DNA Diagnostics Center
4.48 Transgenomic Closes Public Offering of Stock, Warrants
4.49 Qiagen Discloses $114.2M Price Tag for Enyzmatics Acquisition
4.51 GenomeDx Biosciences Implements Clarity LIMS
4.52 Merck Serono and Sysmex Inostics Announce Testing Center
4.53 Lifecode Receives CAP Accreditation, Discloses Funding
4..54 Baylor College of Medicin, Miraca Holdings finalize joint venture.
4.55 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
4.57 Trinity Biotech Revenues Grow by 15%
4.58 Google’s Latest Healthcare Initiative
4.60 Agena Bioscience Launches Smaller Format MassArray
4.61 QuantRx® Biomedical Provides Update on Technological Progress
4.62 The Journal of Molecular Diagnostics Publishes Special Article
4.63 Caprion Licenses Indi's Xpresys as Part of Larger Clinical Push
4.64 MDxHealth's ConfirmMDx Genes Detect Prostate Cancer
4.65 Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health Has Received Accreditation
4.66 Nuclea Bio Plans Entry into Clinical Proteomics
4.67 Personal Genome Diagnostics Aims for FDA Clearance
4.68 Enzo Biochem Announces New Molecular Platform
4.69 Multiplicom, Premaitha Develop CE-IVDs
4.70 Regulating the Next Generation of Genetic Testing
4.71 BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
4.72 Cytogenetics Become First Certified Lab to Offer Microarray Testing
4.73 Results Support Clinical Validity of Quantose IGT(TM) Diabetes Test
4.74 Accelerate Diagnostic Revenues Rise Sharply
4.75 NanoString's Q4 Revenues J Percent
4.76 New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
4.77 HTG Molecular Repo Percent Increase Revenues
4.80 Genomic Vision, Quest Extend Pact for Molecular Combing Technology
4.81 ACT Genomics Raises $8M in Private Funding Round
4.82 NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation
4.83 Invitae Goes Public with $101.6M Offering
4.84 Quidel Q4 Revenues G Percent on Infectious Disease Sales
4.85 Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics
4.86 Premaitha Iona NIPT Lands CE Mark
4.87 Sera Increases Series B Round to $25M with $5M from Gates Foundation
4.88 T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
4.89 Invitae Amends IPO Filing Targeting up to $92.3M
4.90 Biofortuna Closes $2.2M Funding Round
4.91 Roche MDx Sales Help Dri Diagnostics Revenues up 3 Percent
4.92 AltheaDx Increases Target Amount on Proposed IPO to $74.3M
4.93 BioMerie Revenues Increase 7 Percent
4.94 Cypher Genomics and Sequenom Announce Development Agreement
4.95 Abcam to Acquire Firefly BioWorks for $28M
4.97 Human Longevity, Genentech Ink Deal to Sequence Thousands of Genomes
4.98 GenMark Proje Percent Growth in Q4 Revenues
4.99 Amarantus Acquires DioGenix for up to $10.9M
4.100 Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake
4.101 DiaCarta Raises $8M in Series A Round
4.102 Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification
4.103 Adaptive Biotechnologies Acquires Sequenta
4.104 Aegis Sciences Acquires MDx Firm Diagnovus
4.105 Interleukin Genetics Secures $10M in Financing
4.106 Premaitha NIPT Test Receives ISO Certification
4.107 HTG Molecular Diagnostics Files for IPO of up to $60M
4.108 CardioDx Raises $35M
4.109 MolecularMD Receives CAP Accreditation
4.110 14M Genomics Secures £12.5M Equity Financing for Oncology Dx
4.111 Protagen Closes First Part of Financing Round
4.112 Glyconics Inks Exclusive Licensing Deal
4.113 Great Basin Scientific Begins Trial for Staph Assay
4.114 Response Genetics Receives NYS Approval for Cancer Test
4.115 Claritas Genomics Adopts NextCode Health Platform to Interpret NGS Tests
4.116 FDA Clears Quidel's MDx for Bordetella Pertussis
4.117 FDA Clears Additional Flu Strains for Focus' MDx Assay
4.118 Novacyt Raises $3.8M in Private Equity
4.119 Good Start Genetics Licenses PGS Technology from Johns Hopkins
4.120 Metamark's Cambridge Lab Receives CAP Accreditation
4.121 Australia's VCGS Inks Deal with Illumina to Develop NIPT
4.123 Personalized Medicine Firm Newtopia Garners Investment from Bloom Burton
4.124 Roche to Acquire Ariosa Diagnostics
5. Country Market Sizes – North America
5.1 United States of America
5.1.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
5.1.2 Predictive Testing – Volumes, Prices, Revenues
5.1.3 Pharmacogenomic Testing – Volumes, Prices, Revenues
5.1.4 All Genetic testing – Volumes, Prices, Revenues
5.2 Canada
5.2.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
5.2.2 Predictive Testing – Volumes, Prices, Revenues
5.2.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
5.2.4 All Genetic testing – Volumes, Prices, Revenues
6. Country Markets – Europe
6.1 France
6.1.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
6.1.2 Predictive Testing – Volumes, Prices, Revenues
6.1.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
6.1.4 All Genetic testing – Volumes, Prices, Revenues
6.2 Germany
6.2.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
6.2.2 Predictive Testing – Volumes, Prices, Revenues
6.2.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
6.2.4 All Genetic testing – Volumes, Prices, Revenues
6.3 United Kingdom
6.3.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
6.3.2 Predictive Testing – Volumes, Prices, Revenues
6.3.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
6.3.4 All Genetic testing – Volumes, Prices, Revenues
6.4 Spain
6.4.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
6.4.2 Predictive Testing – Volumes, Prices, Revenues
6.4.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
6.4.4 All Genetic testing – Volumes, Prices, Revenues
6.5 Italy
6.5.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
6.5.2 Predictive Testing – Volumes, Prices, Revenues
6.5.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
6.5.4 All Genetic testing – Volumes, Prices, Revenues
6.6 Russia
6.6.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
6.6.2 Predictive Testing – Volumes, Prices, Revenues
6.6.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
6.6.6 All Genetic testing – Volumes, Prices, Revenues
6.7 Remainder of Europe and Former Soviet Union
6.7.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
6.7.2 Predictive Testing – Volumes, Prices, Revenues
6.7.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
6.7.4 All Genetic testing – Volumes, Prices, Revenues
7. Country Markets – Asia Pacific
7.1 China
7.1.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
7.1.2 Predictive Testing – Volumes, Prices, Revenues
7.1.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
7.1.4 All Genetic testing – Volumes, Prices, Revenues
7.2 Japan
7.2.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
7.2.2 Predictive Testing – Volumes, Prices, Revenues
7.2.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
7.2.4 All Genetic testing – Volumes, Prices, Revenues
7.3 South Korea
7.3.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
7.3.2 Predictive Testing – Volumes, Prices, Revenues
7.3.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
7.3.4 All Genetic testing – Volumes, Prices, Revenues
7.4 India
7.4.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
7.4.2 Predictive Testing – Volumes, Prices, Revenues
5.1.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
7.4.4 All Genetic testing – Volumes, Prices, Revenues
7.5 Australia
7.5.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
7.5.2 Predictive Testing – Volumes, Prices, Revenues
7.5.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
7.5.4 All Genetic testing – Volumes, Prices, Revenues
7.6 Rest of Asia Pacific
7.6.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
7.6.2 Predictive Testing – Volumes, Prices, Revenues
7.6.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
7.6.6 All Genetic testing – Volumes, Prices, Revenues
8. Country Markets – Latin America, Africa & The Middle East
8.1 Brazil
8.1.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
8.1.2 Predictive Testing – Volumes, Prices, Revenues
8.1.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
8.1.4 All Genetic testing – Volumes, Prices, Revenues
8.2 Mexico
8.2.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
8.2.2 Predictive Testing – Volumes, Prices, Revenues
8.2.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
8.2.6 All Genetic testing – Volumes, Prices, Revenues
8.3 Rest of Latin America
8.3.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
8.3.2 Predictive Testing – Volumes, Prices, Revenues
8.3.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
8.3.4 All Genetic testing – Volumes, Prices, Revenues
8.4 Africa & The Middle East
8.4.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
8.4.2 Predictive Testing – Volumes, Prices, Revenues
8.4.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
8.4.4 All Genetic testing – Volumes, Prices, Revenues
9. Global Market Summary
9.1 Global Market
9.1.1 Prenatal and Newborn Testing – Volumes, Prices, Revenues
9.1.2 Predictive Testing – Volumes, Prices, Revenues
9.1.3 Pharmacogenomics Testing – Volumes, Prices, Revenues
9.1.6 All Genetic testing – Volumes, Prices, Revenues
10. The Future of Genetic Testing
Appendices
I. United States Medicare System: Janua
laboratory Fees Schedule – National Limit and
Midpoint
II Methodology
II.1 Authors
II.2 Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report